12.30
p.m. – 02.00 p.m. |
LUNCH DEBATE SPONSORED BY BOEHRINGER INGELHEIM |
|
|
|
Risk
for patients with metabolic syndrome
Co-chair
by: To be advised |
|
 |
|
The
cardiologist’s point of
view..............................................................................................................
P. Henry (France) |
|
|
| |
|
The
diabetologist’s point of
view..........................................................................................................
B. Verges (France) |
|
|
| |
|
The
nephrologist’s point of
view.........................................................................................................
J.-M. Halimi (France) |
|
|
|
|
|
Management
of MS and DM: emerging concepts
Co-chair
by: J.-P. Després
(Canada) & M.-R. Taskinen
(Finland) |
|
| |
|
The
fatty liver as a target for treatment
in the metabolic syndrome ...........................................
H. Yki-Jarvinen (Finland) |
|
|
| |
|
New
genes and targets for diabetes
mellitus ...................................................................................
M. Hayden (Canada) |
|
|
| |
|
The
effect of atorvastatin in patients
with metabolic syndrome
participating
in the IDEAL study ........................................................................................................
A. Olsson (Sweden) |
|
|
| |
|
Nuclear
receptors controlling the metabolic
syndrome and type 2 diabetes
........................................
B. Staels (France) |
|
|
